JP4312594B2 - 新規な二環式及び三環式カンナビノイド - Google Patents
新規な二環式及び三環式カンナビノイド Download PDFInfo
- Publication number
- JP4312594B2 JP4312594B2 JP2003511769A JP2003511769A JP4312594B2 JP 4312594 B2 JP4312594 B2 JP 4312594B2 JP 2003511769 A JP2003511769 A JP 2003511769A JP 2003511769 A JP2003511769 A JP 2003511769A JP 4312594 B2 JP4312594 B2 JP 4312594B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- independently
- rings
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930003827 cannabinoid Natural products 0.000 title description 22
- 239000003557 cannabinoid Substances 0.000 title description 22
- 229940065144 cannabinoids Drugs 0.000 title description 14
- 125000002619 bicyclic group Chemical group 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 70
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 description 81
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 35
- 125000000623 heterocyclic group Chemical group 0.000 description 29
- 125000003545 alkoxy group Chemical group 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 22
- 229910052760 oxygen Inorganic materials 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 229910052717 sulfur Inorganic materials 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000012300 argon atmosphere Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- -1 1,1-dimethylheptyl Chemical group 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 230000001766 physiological effect Effects 0.000 description 9
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 8
- 108050007331 Cannabinoid receptor Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XKRHRBJLCLXSGE-VNCLPFQGSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol Chemical class C1C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 XKRHRBJLCLXSGE-VNCLPFQGSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000007429 general method Methods 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XZFDKWMYCUEKSS-UHFFFAOYSA-N 6,6-Dimethylbicyclo[3.1.1]heptan-2-one Chemical compound C1C2C(C)(C)C1CCC2=O XZFDKWMYCUEKSS-UHFFFAOYSA-N 0.000 description 6
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 6
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 6
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 6
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 0 CCC1(C2(C)C(C)CC12)c(c(C)cc(NC=*)c1)c1N Chemical compound CCC1(C2(C)C(C)CC12)c(c(C)cc(NC=*)c1)c1N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 5
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- PWUQQUZMSBIBME-UHFFFAOYSA-N 1-(1-hex-1-enylcyclopentyl)-3,5-dimethoxybenzene Chemical compound C=1C(OC)=CC(OC)=CC=1C1(C=CCCCC)CCCC1 PWUQQUZMSBIBME-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 4
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000003435 aroyl group Chemical group 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 2
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 2
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 2
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- OENPEKQPBXTXSY-UHFFFAOYSA-N 1,3-dimethoxy-5-(2-methyloct-7-yn-2-yl)benzene Chemical compound COC1=CC(OC)=CC(C(C)(C)CCCCC#C)=C1 OENPEKQPBXTXSY-UHFFFAOYSA-N 0.000 description 2
- IGJYDSUUFKFGLV-UHFFFAOYSA-N 1-(1-hexylcyclopentyl)-3,5-dimethoxybenzene Chemical compound C=1C(OC)=CC(OC)=CC=1C1(CCCCCC)CCCC1 IGJYDSUUFKFGLV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000037415 AIDS wasting syndrome Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126559 Compound 4e Drugs 0.000 description 2
- 208000003577 HIV wasting syndrome Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125872 compound 4d Drugs 0.000 description 2
- 229940125801 compound 7f Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FQWPJJFMSTXDCG-UHFFFAOYSA-N pentylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCCCC)C1=CC=CC=C1 FQWPJJFMSTXDCG-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 150000003505 terpenes Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229930006718 (+)-alpha-pinene Natural products 0.000 description 1
- 229930006717 (+)-beta-pinene Natural products 0.000 description 1
- GRWFGVWFFZKLTI-RKDXNWHRSA-N (+)-α-pinene Chemical compound CC1=CC[C@H]2C(C)(C)[C@@H]1C2 GRWFGVWFFZKLTI-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- JNIOIXZHBRHAAJ-WWDZGPRUSA-N (2r)-2-[4-(2-hexyl-1,3-dithiolan-2-yl)-2,6-dihydroxyphenyl]-6,6-dimethylbicyclo[3.1.1]heptan-4-one Chemical compound C=1C(O)=C([C@H]2C3CC(C3(C)C)C(=O)C2)C(O)=CC=1C1(CCCCCC)SCCS1 JNIOIXZHBRHAAJ-WWDZGPRUSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- OUPICNWXPVNWII-RTBURBONSA-N (6ar,10ar)-3-(2-hexyl-1,3-dithiolan-2-yl)-1-hydroxy-6,6-dimethyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromen-9-one Chemical compound CC([C@@H]1CCC(=O)C[C@H]1C1=C(O)C=2)(C)OC1=CC=2C1(CCCCCC)SCCS1 OUPICNWXPVNWII-RTBURBONSA-N 0.000 description 1
- WGMOPSGYXSGPNM-RTBURBONSA-N (6ar,10ar)-3-(8-bromo-2-methyloctan-2-yl)-1-hydroxy-6,6-dimethyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromen-9-one Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(CCCCCCBr)C)=CC(O)=C3[C@@H]21 WGMOPSGYXSGPNM-RTBURBONSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- ODDXNFVRDOKBDC-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)cyclopentane-1-carbaldehyde Chemical compound COC1=CC(OC)=CC(C2(CCCC2)C=O)=C1 ODDXNFVRDOKBDC-UHFFFAOYSA-N 0.000 description 1
- CDDDRVNOHLVEED-UHFFFAOYSA-N 1-cyclohexyl-3-[1-[[1-(cyclohexylcarbamoylamino)cyclohexyl]diazenyl]cyclohexyl]urea Chemical compound C1CCCCC1(N=NC1(CCCCC1)NC(=O)NC1CCCCC1)NC(=O)NC1CCCCC1 CDDDRVNOHLVEED-UHFFFAOYSA-N 0.000 description 1
- UHLUIHGMQCTEBS-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-1,3-dithiane Chemical compound COC1=CC(OC)=CC(C2SCCCS2)=C1 UHLUIHGMQCTEBS-UHFFFAOYSA-N 0.000 description 1
- DTQQPUUHFWGYIF-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-8-trimethylsilyloct-7-yn-2-ol Chemical compound COC1=CC(OC)=CC(C(C)(O)CCCCC#C[Si](C)(C)C)=C1 DTQQPUUHFWGYIF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VMMIDNRMPRPOFS-UHFFFAOYSA-N 5-(1-hex-1-enylcyclopentyl)benzene-1,3-diol Chemical compound C=1C(O)=CC(O)=CC=1C1(C=CCCCC)CCCC1 VMMIDNRMPRPOFS-UHFFFAOYSA-N 0.000 description 1
- HCOGNOPKMJYAJJ-UHFFFAOYSA-N 5-(1-hexylcyclopentyl)benzene-1,3-diol Chemical compound C=1C(O)=CC(O)=CC=1C1(CCCCCC)CCCC1 HCOGNOPKMJYAJJ-UHFFFAOYSA-N 0.000 description 1
- HWXMWEWLBKPPBD-UHFFFAOYSA-N 6-bromohex-1-ynyl(trimethyl)silane Chemical compound C[Si](C)(C)C#CCCCCBr HWXMWEWLBKPPBD-UHFFFAOYSA-N 0.000 description 1
- AAIHVZNCFQTVCA-UHFFFAOYSA-N 9-nor-9β-hydroxyhexahydrocannabinol Chemical compound C1C(O)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 AAIHVZNCFQTVCA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- CTXISPJIIQLCQC-UHFFFAOYSA-N N(=[N+]=[N-])C=1C(=NC=CC1)C1=NC=CC=C1.[Zn] Chemical group N(=[N+]=[N-])C=1C(=NC=CC1)C1=NC=CC=C1.[Zn] CTXISPJIIQLCQC-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
- JSRUBHLVTWPMOD-UHFFFAOYSA-N [7-(3,5-dimethoxyphenyl)-7-methyloct-1-ynyl]-trimethylsilane Chemical compound COC1=CC(OC)=CC(C(C)(C)CCCCC#C[Si](C)(C)C)=C1 JSRUBHLVTWPMOD-UHFFFAOYSA-N 0.000 description 1
- QUQMFQQTMRYQNN-UHFFFAOYSA-N [7-chloro-7-(3,5-dimethoxyphenyl)oct-1-ynyl]-trimethylsilane Chemical compound COC1=CC(OC)=CC(C(C)(Cl)CCCCC#C[Si](C)(C)C)=C1 QUQMFQQTMRYQNN-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- VBWIZSYFQSOUFQ-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#CC1CCCCC1 VBWIZSYFQSOUFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- ZFZKDGSYCAZGBZ-UHFFFAOYSA-N dichloromethane;nitromethane Chemical compound ClCCl.C[N+]([O-])=O ZFZKDGSYCAZGBZ-UHFFFAOYSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- VAUKWMSXUKODHR-UHFFFAOYSA-M pentyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC)C1=CC=CC=C1 VAUKWMSXUKODHR-UHFFFAOYSA-M 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Chemical group 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
- C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Description
{式中、Yは、=C=O、=CH-(CH2)f-Y1-(CH2)g-Y2、=C=N-Y3、=CH-NY4Y5、=CH-(CH2)h-Y6、-C(O)N(Y7)-、-N(Y7)C(O)-、=NY11、=N-(CH2)f-Y1-(CH2)g-Y2、スピロ環又はCY9Y10であり(すべての異性体を含む)[ここで、Y1は、独立して、O、CO、C(O)O、OCO又はCH2であり;Y2は、独立して、H、ハロゲン、CN、CF3、N3、OH、COOH、アルコキシ、アシロキシ、NCS、NCO又はNY7Y8であり;Y3は、独立して、-OH、-NH2、アルコキシ、アルキル、-(CH2)n-NR10R11、-(CH2)n-CO2R(ここで、RはH又はアルキルである)、-O-(CH2)n-NR10R11、-O-(CH2)n-CO2R又は-O-(CH2)n-CONR10R11であり;Y4は、独立して、H、OH、アルコキシ又はアルキルであり;Y5は、独立して、H、OH、アルコキシ又はアルキルであり、ここで、Y4及びY5は、共にOHであることはなく、及び共にアルコキシであることもなく;Y6は、独立して、H、ハロゲン、CN、COOH、COアルキル、CF3、SO2アルキル、COフルオロアルキル、N3、OH、アルコキシ、アシロキシ、NCS、NCO又はNY7Y8であり;Y7は、独立して、H:アルキル:ヒドロキシアルキル:芳香環:アルキル、アルコキシ、ハロゲン及びCF3から選ばれる少なくとも1の置換基で置換された芳香環:複素環:又は複素芳香環であり;Y8は、独立して、H:アルキル:ヒドロキシアルキル:芳香環:アルキル、アルコキシ、ハロゲン及びCF3から選ばれる少なくとも1の置換基で置換された芳香環:複素環:又は複素芳香環であり、あるいは、Y7及びY8は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する3−7員飽和複素環の一部を形成し;Y9は、独立して、H、アルキル又はアルコキシカルボニルメチルであり;Y10は、独立して、H、アルキル又はアルコキシカルボニルメチルであり;Y11は、H、アルキル、CO、CN、CO-アルキル、SO2-アルキル又はCF3であり;fは0−約5の整数であり;gは0−約5の整数であり;hは0−約5の整数であり;nは0−約4の整数である];R1及びR2は、互いに独立して、H、OH、ハロゲン、アルキル、-O-アルキル、NH2、NO2、CN、アシル、アロイル、ベンゾイル、置換ベンゾイル、アリールアルキル、置換アリールアルキル、フェナシル、置換フェナシル、-O-アルキル-NR10R11、-O-アルキル-COOR(ここで、RはH又はアルキルである)、-O-アルキル-CONR10R11、OCOCH3、-N(アルキル)2、-CO(アルキル)X又は-OCO(アルキル)X(ここで、Xは、H、ジアルキルアミノ、シクロアミン、炭素環、複素環、芳香環又は複素芳香環であり;R10及びR11は、独立して、H、アルキル、ヒドロキシアルキルであるか、又はR10及びR11は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する3−7員飽和複素環の一部を形成する)であり;R3は、
[ここで、Zは、CR12R13(ここで、R12及びR13は、互いに独立して、H又はアルキルである)、S、O、NH、N(CH3)、SO又はSO 2 であり;R4は、-(CH2)j-R5、-(CH2)j-A-(CH2)k-R5又は-(CH2)j-A-(CH2)k-B-R5(ここで、A及びBは、互いに独立して、-CH2-CH2-、-CH=CH-、-C≡C-、O、S、SO、SO2又はNHであり;R5は、H、ハロゲン、CN、CF3、N3、COOH、NH2、N(CH3)2、+N(CH3)3、Sn(アルキル)3、フェニル、COOR(ここで、RはH又はアルキルである)、炭素環、複素環、芳香環、複素芳香環、2−約5個の環を有する多炭素環構造、2−5個の環を有する多複素環構造又はCONR10R11(ここで、R10及びR11は、互いに独立して、H、アルキル、ヒドロキシアルキルであるか、又はR10及びR11は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する5又は6員飽和複素環の一部を形成する)であり;jは0−約7の整数であり;kは0−約7の整数である)であり;nは0−約4の整数である]である。}
=CH-(CH2)h-Y6
(ここで、Y6は、I、CN又はN3であり、hは約1−約3の整数であるか;又はY6は、I又はN3であり、hは0−約3の整数である)であり;R1及びR2は、独立して、H、OH、アルキル又はアルコキシであり;R3は、
[ここで、R16は、H、ハロゲン、CN、CF3、N3、COOH、NH2、N(CH3)2、+N(CH3)3、Sn(アルキル)3、フェニル、COOR(ここで、RはH又はアルキルである)、炭素環、複素環、芳香環、複素芳香環、2−約5個の環を有する多炭素環構造、2−約5個の環を有する多複素環構造又はCONR10R11(ここで、R10及びR11は、互いに独立して、H、アルキル、ヒドロキシアルキルであるか、又はR10及びR11は、一緒になって、N、O及びSから選ばれるさらに少なくとも1以下のへテロ原子を含有する5又は6員飽和複素環の一部を形成する)であり;nは0−約7の整数である]である。
{式中、Xは、=C=O、=CH-(CH2)f-X1-(CH2)g-X2、=C=N-X3、=CH-NX4X5、=CH-(CH2)h-X6、-C(O)N(X7)-、-N(X7)C(O)-、=NX11、=N-(CH2)f-X1-(CH2)g-X2、スピロ環又はCX9X10であり(すべての異性体を含む)[ここで、X1は、独立して、O、CO、C(O)O、OCO又はCH2であり;X2は、独立して、H、ハロゲン、CN、CF3、N3、OH、COOH、アルコキシ、アシロキシ、NCS、NCO又はNX7X8であり;X3は、独立して、-OH、-NH2、アルコキシ、アルキル、-(CH2)n-NR10R11、-(CH2)n-CO2R(ここで、RはH又はアルキルである)、-O-(CH2)n-NR10R11、-O-(CH2)n-CO2R又は-O-(CH2)n-CONR10R11であり;X4は、独立して、H、OH、アルコキシ又はアルキルであり;X5は、独立して、H、OH、アルコキシ又はアルキルであり、ここで、X4及びX5は、共にOHであることはなく、及び共にアルコキシであることもなく;X6は、独立して、H、ハロゲン、CN、COOH、COアルキル、CF3、SO2アルキル、COフルオロアルキル、N3、OH、アルコキシ、アシロキシ、NCS、NCO又はNX7X8であり;X7は、独立して、H:アルキル:ヒドロキシアルキル:芳香環:アルキル、アルコキシ、ハロゲン及びCF3から選ばれる少なくとも1の置換基で置換された芳香環:複素環:又は複素芳香環であり;X8は、独立して、H:アルキル:ヒドロキシアルキル:芳香環:アルキル、アルコキシ、ハロゲン及びCF3から選ばれる少なくとも1の置換基で置換された芳香環:複素環:又は複素芳香環であり、あるいは、X7及びX8は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する3−7員飽和複素環の一部を形成し;X9は、独立して、H、アルキル又はアルコキシカルボニルメチルであり;X10は、独立して、H、アルキル又はアルコキシカルボニルメチルであり;X11は、H、アルキル、CO、CN、COアルキル、SO2アルキル又はCF3であり;fは0−約3の整数であり;gは0−約3の整数であり;hは0−約3の整数であり;nは0−約4の整数である];R1は、H、OH、ハロゲン、アルキル、-O-アルキル、NH2、NO2、CN、アシル、アロイル、ベンゾイル、置換ベンゾイル、アリールアルキル、置換アリールアルキル、フェナシル、置換フェナシル、-O-アルキル-NR10R11、-O-アルキル-COOR(ここで、RはH又はアルキルである)、-O-アルキル-CONR10R11、OCOCH3、-N(アルキル)2、-CO(アルキル)X又は-OCO(アルキル)X(ここで、Xは、H、ジアルキルアミノ、シクロアミン、炭素環、複素環、芳香環又は複素芳香環であり;R10及びR11は、互いに独立して、H、アルキル、ヒドロキシアルキルであるか、又はR10及びR11は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する3−7員飽和複素環の一部を形成する)であり;R3は、
[ここで、Zは、CR12R13(ここで、R12及びR13は、互いに独立して、H又はアルキルである)、S、O、NH、N(CH3)、SO又はSO 2 であり;R4は、-(CH2)j-R5、-(CH2)j-A-(CH2)k-R5又は-(CH2)j-A-(CH2)k-B-R5(ここで、A及びBは、互いに独立して、-CH2-CH2-、-CH=CH-、-C≡C-、O、S、SO、SO2又はNHであり;R5は、H、ハロゲン、CN、CF3、N3、COOH、NH2、N(CH3)2、+N(CH3)3、Sn(アルキル)3、フェニル、COOR(ここで、RはH又はアルキルである)、炭素環、複素環、芳香環、複素芳香環、2−約5個の環を有する多炭素環構造、2−5個の環を有する多複素環構造又はCONR10R11(ここで、R10及びR11は、互いに独立して、H、アルキル、ヒドロキシアルキルであるか、又はR10及びR11は、一緒になって、N、O及びSから選ばれるさらに1以下のへテロ原子を含有する5又は6員飽和複素環の一部を形成する)であり;jは0−約7の整数であり;kは0−約7の整数である)であり;nは0−約4の整数である]である。}
=CH-(CH2)h-X6
(ここで、X6は、I、CN、N3又はCOOHであり、hは約1−約3の整数であるか;又はX6は、I、N3又はCOOHであり、hは0−約3の整数である)であり;R1は、H、OH、アルキル又はアルコキシであり;R3は、
1.レゾルシノールの合成
スキーム1に示す方法によって、(3,5-ジメトキシフェニル)シクロペンタンカルボキシアルデヒド(Papahatjisら, Chemistry Letters, 192(2001)に記載の方法によって調製したもの)を出発原料として、レゾルシノール化合物1a及び1b(スキーム1に示す)を合成した。
(ブチルメチレン)トリフェニルホスホラン
乾燥THF(0.18M)にペンチルトリフェニルホスホニウム臭化物(5当量)を含む懸濁液に、アルゴン雰囲気下、0℃において、カリウムビス(トリメチルシリル)アミド(4.9当量)を添加した。混合物を10℃に加温し、さらに30分間撹拌して、完全にオレンジ色のイリドを形成させた。得られたスラリーを、1-(3,5-ジメトキシフェニル)-1-(ヘキサ-1-エニル)-シクロペンタンの調製に使用した。
上記(ブチルメチレン)トリフェニルホスホランのスラリーに、アルゴン雰囲気下、10℃において、(3,5-ジメトキシフェニル)シクロペンタンカルボキシアルデヒド(1当量)の乾燥THF(0.21M)溶液を滴下した。反応混合物を45分間撹拌し、終了後、飽和塩化アンモニウム水溶液を添加することによって、反応を停止させた。有機相を分離し、水相をジエチルエーテルにて2回抽出した。有機相を合わせ、ブラインにて洗浄し、MgSO4にて乾燥させ、溶媒を減圧下で蒸発させて、オイルを得た。溶離剤として5%ジエチルエーテル−石油エーテルを使用し、粗製生成物を、短いシリカゲルカラムを通して精製して、題記の化合物を収率96%で得た。
1-(3,5-ジメトキシフェニル)-1-(ヘキサ-1-エニル)-シクロペンタン(1当量)の酢酸エチル(0.11M)溶液に、10%Pd/C(17%,w/w)を添加し、得られた懸濁液を水素雰囲気下、室温において、一夜激しく撹拌した。セライトを介する瀘過によって触媒を除去し、濾液を、減圧下で蒸発させて粗製生成物を得た。5%ジエチルエーテル−石油エーテルを使用する短いシリカゲルカラムでの精製によって、題記の化合物を収率95%で得た。
1-(3,5-ジメトキシフェニル)-1-ヘキシル-シクロペンタン(1当量)の乾燥塩化メチレン(0.04M)溶液に、アルゴン雰囲気下、−78℃において、三臭化ホウ素(2.5当量、1M塩化メチレン溶液)を添加した。添加後、反応温度を3時間で−20℃に上昇させた。反応が完了するまで、この温度において撹拌を続けた。0℃において、メタノール及び氷を添加することによって、未反応の三臭化ホウ素を破壊した。得られた混合物を室温に加温し、40分間撹拌し、真空下で溶媒を除去した。残留するオイルを酢酸エチルで希釈し、溶液を飽和炭酸水素ナトリウム水溶液、水及びブラインにて洗浄した。有機相をMgSO4にて乾燥させ、濾過し、減圧下で濃縮した。フラッシュカラムクロマトグラフィー(溶離剤として40%ジエチルエーテル−石油エーテルを使用)によって、題記の化合物を収率90%で得た。
1H NMR(500MHz, CDCl3)δ: 6.36(d, J=1.6Hz, 2H), 6.19(t, J=1.6Hz, 1H), 5.78(brs, 2H, OH), 1.83-1.77(m, 2H), 1.73-1.58(m, 6H), 1.51-1.48(m, 2H), 1.22-1.12(m, 6H), 1.02-0.94(m, 2H), 0.83(t, J=7.1Hz, 3H)
1-(3,5-ジメトキシフェニル)-1-(ヘキサ-1-エニル)-シクロペンタン(1当量)の乾燥ヘキサン(0.05M)溶液に、アルゴン雰囲気下、0℃において、9-ヨード-9-BBN(2.3当量、1Mヘキサン溶液)を添加した。同じ温度において、混合物を間3.5時間撹拌し、ついで、反応温度を27℃に上げた。反応が完了するまで、この温度で撹拌を続けた。真空下で揮発性物質を除去し、残留するオイルをジエチルエーテルに溶解し、エタノールアミン(2.4当量)のTHF(1.4M)溶液を添加して、9-BBN-エタノールアミン付加物を自然に沈殿させた。懸濁液を2.5時間撹拌し、白色沈殿を瀘過し、濾液を減圧下で濃縮させて、オイルを得た。溶離剤として40%ジエチルエーテル−石油エーテルを使用するシリカゲル上でのフラッシュカラムクロマトグラフィーによる精製の結果、題記の化合物を収率82%で得た。
1H NMR(500MHz, CDCl3)δ: 6.44(d, J=1.9Hz, 2H), 6.17(t, J=1.9Hz, 1H), 5.66(d, J=11.0Hz, 1H), 5.28(dt, J=11.0Hz, J=7.3Hz, 1H), 5.14(brs, 2H, OH), 2.01-1.85(m, 4H), 1.80-1.65(m, 6H), 1.15-1.07(m, 4H), 0.77(t, J=6.81Hz, 3H)
[7-(3,5-ジメトキシフェニル-1,3-ジチアン-7-イル)-1-ヘプチニル]トリメチルシラン
2-(3,5-ジメトキシフェニル)-1,3-ジチアン(1当量)の乾燥テトラヒドロフラン(0.5M)溶液を、アルゴン雰囲気下で−30℃に冷却し、n-ブチルリチウム(1.2当量、1.6Mヘキサン溶液)を滴下した。黄−褐色の反応混合物を、この温度において2時間撹拌し、色が黄−褐色から明るい黄色に変化した時点で、(6-ブロモ-1-ヘキシニル)トリメチルシラン(1.2当量)を1滴ずつ添加した。反応混合物を一夜放置して、室温に加温し、水に注ぎ、ジエチルエーテルで抽出した。合わせた有機性抽出液を乾燥し、エーテルを除去して、粗製生成物を得た後、これを、シリカゲル上(15%ジエチルエーテル−石油エーテル)で精製して、題記化合物を、オイルとして収率86%で得た。
元素分析(C21H32O2S2Siについて):
理論値 C 61.72; H 7.89
測定値 C 61.49; H 8.24
[7-(3,5-ジメトキシフェニル-1,3-ジチアン-7-イル)-1-ヘプチニル]トリメチルシラン(1当量)の10%水性メタノール(0.1M)溶液を氷浴中で冷却し、撹拌心ながら、ビス(トリフルオロアセトキシ)ヨードベンゼン(1.5当量)を少量ずつ添加した。反応混合物をさらに10分間撹拌し、炭酸水素ナトリウムに注いだ。混合物をジエチルエーテルで抽出し、エーテル抽出液を合わせ、乾燥し、溶媒を除去して、オイルを得た後、このオイルを、シリカゲル上でのクロマトグラフィーにて精製して、題記化合物を収率90%で得た。
元素分析(C18H26O3Siについて):
理論値 C 67.88; H 8.23
測定値 C 67.56; H 8.55
[7-(3,5-ジメトキシフェニル-7-オキソ-1-ヘプチニル]トリメチルシラン(1当量)を無水のエーテル(0.5M)に溶解し、溶液を、アルゴン雰囲気下、氷浴中で冷却し、臭化メチルマグネシウム(2当量、3Mジエチルエーテル溶液)を滴下した。淡い灰色の溶液を室温に加温し、さらに1時間撹拌した。反応混合物を飽和塩化アンモニウム溶液に注ぎ、有機相を分離し、水相をジエチルエーテルにて抽出した。合わせた有機抽出液を乾燥し、エーテルを除去し、短いシリカゲルカラムを通過させた後、純粋な[7-(3,5-ジメトキシフェニル)-7-ヒドロキシ-1-オクチニル]トリメチルシランオイルを収率95%で得た。
1H NMR(CDCl3)δ: 6.47(d, J=2.16Hz, 2H), 6.28(t, J=2.16Hz, 1H), 3.78(s, 6H), 2.14(t, J=7.08Hz, 2H), 1.63-1.06[オーバーラッピングパターン、すなわち、1.63-1.06(m, 6H), 1.25(s, 6H)], 0.10(s, 9H)
元素分析(C20H32O2Siについて):
理論値 C 72.23; H 9.70
測定値 C 71.98; H 9.87
[7-(3,5-ジメトキシフェニル)-7-メチル-1-オクチニル]トリメチルシラン(1当量)を無水のメタノール(0.8M)に溶解し、無水の炭酸カリウム(0.2当量)を添加し、不均質の混合物を、アルゴン雰囲気下、室温において24時間撹拌した。反応混合物を水で希釈し、ジエチルエーテルにて抽出した。エーテル抽出液を乾燥し、回転蒸発によって濃縮し、残渣を、シリカゲル上でのクロマトグラフィーによって精製して、題記化合物を収率76%で得た。
7-(3,5-ジメトキシフェニル)-7-メチル-1-オクチン(1当量)の無水ジクロロメタン(0.1M)溶液を、アルゴン雰囲気下で−40℃に冷却し、三臭化ホウ素(2.5当量、1Mジクロロメタン溶液)を、注射器を介して添加した。1−1.5時間撹拌しながら、反応混合物を0℃に加温し、ついで、飽和炭酸水素ナトリウム溶液にて反応を停止させた。有機相を分離し、乾燥し、溶媒を除去した。残渣を、シリカゲル上でクロマトグラフィー処理(30−40%ジエチルエーテル−石油エーテル)して、題記のレゾルシノールを収率56%で得た。
13C NMR(CDCl3)δ:156.37, 153.11, 105.92, 100.11, 84.76, 68.22, 55.30, 43.77, 37.70, 29.03, 28.79, 23.87, 18.24
スキーム3に示す方法によって、二環式ケトン(例えば、スキーム3に示すa、b、c、d又はeのR基を有する化合物2)を合成した。
レゾルシノール(1当量)及びノピノンジアセテート(約1.3当量、1H NMRによる純度約87%)のクロロホルム(約0.1M)溶液に、0℃において、p-トルエンスルホン酸・1水和物(約1.3当量)を添加した。添加後、反応温度を室温に上げ、生成物の完全な生成を行なうため、撹拌を4時間−3日間続けた。反応混合物を有機溶媒にて希釈し、水、飽和炭酸水素塩水溶液及びブラインにて、順次洗浄した。有機相をMgSO4にて乾燥し、減圧下で溶媒を除去した。残渣をシリカゲル上でクロマトグラフィー処理して、二環式ケトンを得た。
(4R)-4-[4-(1,1'-シクロペンチルヘプチル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン;収率=49%;白色固体;融点=187-188℃
化合物2b
(4R)-4-[4-(1,1'-シクロペンチルヘプテ-2'-ニル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン;収率=47%;白色固体;融点=167-168℃
化合物2c
(4R)-4-[4-(2-ヘキシル-1,3-ジチオラン-2-イル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン;収率=13%;白色固体;融点=160-161℃
1H NMR(500MHz, CDCl3)δ: 6.68(s, 2H, ArH), 5.02(brs, 2H, OH), 3.95(t, J=8.2Hz, 1H), 3.44(dd, J=18.7Hz, J=7.8Hz, 1H), 3.37-3.30(m, 2H), 3.25-3.18(m, 2H), 2.60(dd, J=19.5Hz, J=8.5Hz, 1H), 2.58(t, J=4.7Hz, 1H), 2.53-2.49(m, 1H), 2.44(d, J=10.8Hz, 1H), 2.30(m, 1H), 2.26-2.22(m, 2H), 1.36(s, 3H), 1.27-1.19(m, 8H), 0.99(s, 3H), 0.85(t, J=6.5Hz, 3H)
化合物2d
(4R)-4-[4-(7'-ブロモ-1',1'-ジメチルヘプチル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン;収率=41%;明るい黄色固体
題記化合物(2d)を,誘導体化合物4dの調製に使用した。
元素分析(C24H34BrO2について):
理論値 C 63.85;H 7.81
測定値 C 63.99;H 8.20
化合物2e
(4R)-4-[4-(1',1'-ジメチルヘプチ-6'-ニル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン;収率=40%
題記化合物(2e)を,誘導体化合物4eの調製に使用した。
FAB HRMS(C24H34O3について):
理論値 369.2430(M+H+)
測定値 369.2430
(4R)-4-[4-(2-ヘキシル-1,3-ジチオラン-2-イル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2β-ノルピナノール及び(4R)-4-[4-(2-ヘキシル-1,3-ジチオラン-2-イル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2α-ノルピナノールのジオステレオマー混合物の合成
題記混合物(化合物3)をスキーム4に示す方法によって合成した。
アルゴン雰囲気下、−15℃において撹拌した(4R)-4-[4-(2-ヘキシル-1,3-ジチオラン-2-イル)-2,6-ジヒドロキシフェニル]-6,6-ジメチル-2-ノルピナノン(化合物2c)(11mg, 0.025ミリモル)のメタノール(0.5ml)溶液に、ナトリウムボロヒドリッド(3mg, 0.079ミリモル)を添加した。反応混合物を、同じ温度において2.5時間撹拌し、完了後、飽和塩化アンモニウム水溶液の添加によって処理した。真空下で揮発性物質を除去し、残渣を酢酸エチルで抽出した。有機層を、水及びブラインで洗浄し、MgSO4にて乾燥し、溶媒を留去した。残渣をシリカゲル上でのクロマトグラフィーに供して、題記混合物6mg(54%)を白色のガラス質として得た。
3.9-ノル-9-オキソヘキサヒドロカンナビノールの合成
スキーム5に示す方法によって、9-ノル-9-オキソヘキサヒドロカンナビノール(例えば、スキーム5に示すR基a−eをもつ化合物4)を合成した。
アルゴン雰囲気下、0℃において撹拌した二環式ケトン(1当量)の乾燥塩化メチレン−ニトロメタン混合物(0.01−0.05M)溶液に、トリメチルシリルトリフルオロメタンスルホネート(約0.3−1.3当量)を添加した。添加後、混合物を0℃−室温で1−7時間撹拌した。飽和炭酸水素ナトリウム水溶液/ブライン(1/1)にて反応を終了させ、有機溶媒を添加した。有機相を分離し、水相を有機溶媒にて抽出し、合わせた有機相をブラインにて洗浄し、MgSO4にて乾燥した。溶媒の留去に続いて、シリカゲル上でのフラッシュカラムクロマトグラフィーを行い、9-ノル-9-オキソヘキサヒドロカンナビノールを得た。
(-)-トランス-3-(1',1'-シクロペンチルヘプチル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン;収率:75%;白色の泡状
化合物4b
(-)-トランス-3-(1',1'-シクロペンチルヘプト-2'-エニル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン:;収率:73%;白色の泡状
化合物4c
(-)-トランス-3-(2-ヘキシル-1,3-ジチオラン-2-イル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン;収率:83%;白色の泡状;融点=62−64℃(分解)
1H NMR(500MHz, CDCl3)δ: 6.76(d, J=1.8HZ, 1H, ArH), 6.64(d, J=1.8Hz, 1H, ArH), 5.85(s, 1H, OH), 3.94(d, J=14.6Hz, 1H), 3.36-3.30(m, 2H), 3.28-3.21(m, 2H), 2.87(td, J=11.9Hz, J=3.3Hz, 1H), 2.63-2.59(m, 1H), 2.48-2.40(m, 1H), 2.27(m, 2H), 2.18-2.14(m, 2H), 1.96(td, J=11.7Hz, J=2.0Hz, 1H), 1.56-1.45(m, 4H), 1.26-1.19(m, 8H), 1.12(s, 3H), 0.84(t, J=7.0Hz, 3H)
化合物4d
(-)-トランス-3-(7'-ブロモ-1',1'ジメチルヘプチル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン;収率:71%;明るい黄色の泡状
題記化合物(4d)を誘導体化合物6dの調製に使用した。
元素分析(C24H34BrO2について):
理論値 C 63.85;H 7.81
測定値 C 63.99;H 8.20
化合物4e
(-)-トランス-3-(1',1'-ジメチルヘプト-6'-ニル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン
一般的方法に続いて、残渣を、シリカゲルの短いカラムを通過させ、題記化合物(4e)を、さらに精製することなく、誘導体化合物6eの調製に使用した。
化合物5
6a,7,8,9,10,10a-ヘキサヒドロ-3-(2-ヘキシル-1,3-ジチオラン-2-イル)-6,6-ジメチル-6H-ジベンゾ[b,d]ピラン-1,9β-ジオールを、スキーム6に示す方法によって合成した。
アルゴン雰囲気下、−15℃において撹拌した(-)-トランス-3-(2-ヘキシル-1,3-ジチオラン-2-イル)-6,6a,7,8,10,10a-ヘキサヒドロ-1-ヒドロキシ-6,6-ジメチル-9H-ジベンゾ[b,d]ピラン-9-オン(化合物4c)(1当量)のメタノール(約0.05M)溶液に、ナトリウムボロヒドリッド(約5当量)を添加した。反応混合物を同じ温度において撹拌し、完了後、飽和塩化アンモニウム水溶液を添加して反応を終了させた。真空下、揮発性物質を除去し、残渣を、酢酸エチルにて抽出した。有機相を水及びブラインにて洗浄し、MgSO4にて乾燥し、溶媒の留去した。残渣を、シリカゲル上でのクロマトグラフィーに供して、題記化合物を収率69%で得た。
1H NMR(CDCl3)δ: 6.70(d, J=1.7HZ, 1H, ArH), 6.59(d, J=1.7Hz, 1H, ArH), 5.98(brs, 1H), 3.89-3.84(m, 1H, H-9), 3.51-3.49(m, 1H), 3.34-3.21(m, 4H), 2.47(t, J=10.8Hz, 1H), 2.30-1.37(11H, 特に1.38, s, Me), 1.26-1.16(m, 8H), 1.06(s, 3H, Me), 0.84(t, J=6.9Hz, 3H)
スキーム7に示す方法によって、9-ノル-9α-ヒドロキシヘキサヒドロカンナビノール(例えば、スキーム7に示すR基d及びeをもつ化合物6)を合成した。
9-ノル-9-オキソヘキサヒドロカンナビノール(1当量)の無水THF(約0.02M)溶液を、アルゴン雰囲気下において、−78℃に冷却し、K-セレクトライドの1M THF溶液(約5当量)を、ゆっくりと1滴ずつ添加した。反応混合物を、−78℃において2−5時間撹拌し、ついで、水を注意しながら添加して、反応を停止させた。混合物を室温に加温し、10%塩酸に注加し、有機相を分離した。水相を抽出し、合わせた有機相を乾燥し(MgSO4)、溶媒を留去した。残渣を、シリカゲル上でのクロマトグラフィーに供して、9-ノル-9α-ヒドロキシヘキサヒドロカンナビノールを得た。
6a,7,8,9,10,10a-ヘキサヒドロ-3-(7'-ブロモ-1',1'-ジメチルヘプチル)-6,6-ジメチル-6H-ジベンゾ[b,d]ピラン-1,9α-ジオール;収率:60%
題記化合物(6d)を、誘導体化合物7dの調製に使用した。
化合物6e
6a,7,8,9,10,10a-ヘキサヒドロ-3-(1',1'-ジメチルヘプト-6'-ニル)-6,6-ジメチル-6H-ジベンゾ[b,d]ピラン-1,9α-ジオール
題記化合物(6e)を、誘導体化合物6fの調製に使用した。
FAB HRMS(C24H34O3について):
理論値 371.2589(M+H+)
測定値 371.2588
化合物6f
6a,7,8,9,10,10a-ヘキサヒドロ-3-(7'-ト-n-ブチルスズ-1',1'-ジメチルヘプト-6'-エニル)-6,6-ジメチル-6H-ジベンゾ[b,d]ピラン-1,9α-ジオール
方法:
乾燥トルエン5.3ml中に、3-(1',1'-ジメチルヘプト-6'-ニル)-9α-ヒドロキシヘキサヒドロカンナビノール(化合物6e)(100mg、0.27ミリモル)、1,1'-アゾビス(シクロヘキサンカルボニトリル)(20mg)及び塩化トリ-n-ブチルスズ0.16mlを含む混合物を、アルゴン雰囲気下、10時間還流した。混合物を室温に冷却し、トルエンを真空下で除去し、残渣を、シリカゲル上でのクロマトグラフィー(30−50%エチルエーテル−石油エーテル)に供して、題記化合物(6f)130mg(73%)を無色のオイルとして得た。
FAB HRMS(C36H63O3Snについて):
理論値 663.3799(M+H+)
測定値 663.3798
スキーム8に示す方法によって、9-ノル-9β-アジドヘキサヒドロカンナビノール(例えば、スキーム8に示すR基d、f及びgをもつ化合物8)を合成した。
9-ノル-9α-ヒドロキシヘキサヒドロカンナビノール(1当量)、亜鉛アジドビピリジル錯体(約1.5当量)、トリフェニルホスフィン(約4当量)及び無水の有機溶媒(約0.25M)の混合物を、アルゴン雰囲気下で撹拌し、ジイソプロピルアゾカルボキシレート(DIAD、約4当量)の乾燥有機溶媒溶液を、ゆっくりと1滴ずつ添加した。混合物を室温で撹拌し、終了後、シリカゲル上でのクロマトグラフィーに供して、9-ノル-9β-アジドヘキサヒドロカンナビノールを得た。
1-ヒドロキシ-3-(7'-ブロモ-1',1'-ジメチルヘプチル)-6,6-ジメチル-9β-アジド-6a,7,8,8,10,10a-ヘキサヒドロ-6H-ジベンゾ[b,d]ピラン;収率:71%
題記化合物(7d)を化合物8の調製に使用した。
化合物7f
1-ヒドロキシ-3-(7'-トリ-n-ブチルスズ-1',1'-ジメチルヘプト-6'-エニル)-6,6-ジメチル-9β-アジド-6a,7,8,8,10,10a-ヘキサヒドロ-6H-ジベンゾ[b,d]ピラン;収率:72%
題記化合物(7f)を化合物9の調製に使用した。
化合物7g
1-ヒドロキシ-3-(1',1'-ジメチルヘプチル)-6,6-ジメチル-9β-アジド-6a,7,8,9,10,10a-ヘキサヒドロ-6H-ジベンゾ[b,d]ピラン;収率:75%
題記化合物用の前駆体を、既に化合物6に関して記載の方法によって合成した。
IR(AgCl):v=2096cm−1(N3)
9-ノル-9β-アジドヘキサヒドロカンナビノール(スキーム9に示す化合物8及び9)を、スキーム9に示す方法によって合成した。
1-ヒドロキシ-3-(7'-ヨード-1',1'-ジメチルヘプチル)-6,6-ジメチル-9β-アジド-6a,7,8,9,10,10a-ヘキサヒドロ-6H-ジベンゾ[b,d]ピラン
題記化合物(8)を、スキーム9に示す方法によって合成した。
方法:
9β-アジド-3-(7'-ブロモ-1',1'-ジメチルヘプチル)ヘキサヒドロカンナビノール(化合物7d)100mg(0.21ミリモル)を乾燥アセトン5mlに溶解し、ヨウ化ナトリウム63mg(0.42ミリモル)を添加し、溶液を6時間還流した。回転エバポレーターによってアセトンを除去し、残渣をエーテルで抽出した。エーテル抽出物を濃縮し、残渣をクロマトグラフィーに供して、題記化合物(8)88mg(80%)をゴムとして得た。
1-ヒドロキシ-3-(7'-ヨード-1',1'-ジメチルヘプト-6'-エニル)-6,6-ジメチル-9β-アジド-6a,7,8,9,10,10a-ヘキサヒドロ-6H-ジベンゾ[b,d]ピラン
題記化合物(9)を、スキーム9に示す方法によって合成した。
方法:
9-ノル-9β-アジドヘキサヒドロカンナビノール(化合物7f)16mg(0.023ミリモル)を、ジクロロメタン1mlに溶解し、ヨウ素8.7mg(0.034ミリモル)のジクロロメタン(0.5ml)溶液を滴下した。溶液を、室温において15分間撹拌し、0.1M亜硫酸水素ナトリウム水溶液の添加によって過剰のヨウ素を分解した。有機相を分離し、乾燥し(MgSO4)、溶媒を除去した。残渣を、シリカゲル上でのカラムクロマトグラフィーに供して、題記化合物(9)12.8mgを得た。
FAB HRMS(C24H34IN3O2について):
理論値 524.1744(M+H+)
測定値 524.1771
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30522801P | 2001-07-13 | 2001-07-13 | |
PCT/US2002/021961 WO2003005960A2 (en) | 2001-07-13 | 2002-07-11 | Novel bicyclic and tricyclic cannabinoids |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005504736A JP2005504736A (ja) | 2005-02-17 |
JP2005504736A5 JP2005504736A5 (ja) | 2006-01-12 |
JP4312594B2 true JP4312594B2 (ja) | 2009-08-12 |
Family
ID=23179898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003511769A Expired - Fee Related JP4312594B2 (ja) | 2001-07-13 | 2002-07-11 | 新規な二環式及び三環式カンナビノイド |
Country Status (6)
Country | Link |
---|---|
US (2) | US7057076B2 (ja) |
EP (1) | EP1414775B1 (ja) |
JP (1) | JP4312594B2 (ja) |
AU (1) | AU2002320430A1 (ja) |
CA (1) | CA2452881C (ja) |
WO (1) | WO2003005960A2 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE247097T1 (de) | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
US7119108B1 (en) * | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
AU778159B2 (en) | 1999-10-18 | 2004-11-18 | University Of Connecticut, The | Peripheral cannabinoid receptor (CB2) selective ligands |
US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US7329651B2 (en) * | 2001-01-26 | 2008-02-12 | University Of Connecticut | Cannabimimetic ligands |
US7446229B2 (en) * | 2001-07-13 | 2008-11-04 | University Of Connecticut | Bicyclic cannabinoids |
JP4312594B2 (ja) * | 2001-07-13 | 2009-08-12 | ユニバーシティ オブ コネチカット | 新規な二環式及び三環式カンナビノイド |
US7666867B2 (en) * | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
EP1469842A4 (en) * | 2002-01-31 | 2006-04-26 | Pharmos Corp | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS |
CN1678303A (zh) | 2002-08-23 | 2005-10-05 | 康涅狄格大学 | 具有治疗作用的酮类大麻类 |
WO2005097800A1 (en) * | 2004-04-02 | 2005-10-20 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
WO2008001369A1 (en) * | 2006-06-27 | 2008-01-03 | Pharmos Corporation | Use of cb2 receptor agonists for promoting neurogenesis |
WO2008109027A2 (en) | 2007-03-02 | 2008-09-12 | University Of Tennessee Research Foundation, The | Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
US8349876B2 (en) * | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
US8541431B2 (en) | 2008-05-19 | 2013-09-24 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
CA2724733A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine classical cannabinoid compounds and related methods of use |
JP2011520973A (ja) | 2008-05-19 | 2011-07-21 | ユニヴァーシティ オブ テネシー リサーチ ファウンデーション,ザ | ピリジンの非古典的カンナビノイド化合物及び関連する使用方法 |
WO2010041253A1 (en) * | 2008-10-06 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions comprising cb receptor agonists, uses thereof and methods for their preparation |
WO2011006099A1 (en) * | 2009-07-10 | 2011-01-13 | Northeastern University | Angiogenic resorcinol derivatives |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US557636A (en) * | 1896-04-07 | baker | ||
US3041343A (en) | 1959-10-14 | 1962-06-26 | Sandoz Ltd | 4-(thienyl-2'')-and 4-(pyridyl-3'')-5-aminopyrazoles |
US3577458A (en) | 1966-11-14 | 1971-05-04 | Allied Chem | Process for the preparation of isocyanates |
US3465024A (en) | 1966-11-14 | 1969-09-02 | Allied Chem | Process for the preparation of isocyanates |
US3573327A (en) | 1970-03-23 | 1971-03-30 | Searle & Co | 3-(lower alkoxy)-7,8,9,10-tetrahydro-6h-dibenzo-(b,d) pyran-6,9-diones and derivatives thereof |
US3656906A (en) | 1970-04-13 | 1972-04-18 | Little Inc A | Method for detecting and quantitating the presence of cannabinoids and analogs thereof in biological materials and resulting products |
US3838131A (en) | 1972-04-03 | 1974-09-24 | Pfizer | Di(dialkylamino alkoxy)phenanthridines as antiviral agents |
US3915996A (en) | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
GB1436771A (en) | 1973-02-16 | 1976-05-26 | Labaz | Indole derivatives and process for preparing the same |
DE2335136A1 (de) | 1973-07-06 | 1975-01-16 | Schering Ag | 7-hydroxy-delta hoch 8-tetrahydrocannabinole |
US3886184A (en) | 1973-08-03 | 1975-05-27 | Lilly Co Eli | Aminodibenzo(b,d)pyrans |
US3953603A (en) | 1973-11-05 | 1976-04-27 | Eli Lilly And Company | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs |
US3944673A (en) | 1973-11-05 | 1976-03-16 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs |
US3928598A (en) | 1973-11-05 | 1975-12-23 | Lilly Co Eli | Hexahydro-dibenzo{8 b,d{9 pyran-9-ones as an anti-anxiety drug |
US4278603A (en) | 1973-11-05 | 1981-07-14 | Eli Lilly And Company | Novel polymorphic crystalline form of dibenzopyranone |
IL48824A (en) | 1976-01-12 | 1980-05-30 | Yissum Res Dev Co | Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type |
US4036857A (en) | 1976-02-02 | 1977-07-19 | Sharps Associates | Benzopyrans having an unsaturated side chain |
US4087546A (en) | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs |
US4088777A (en) | 1976-02-17 | 1978-05-09 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs |
US4087545A (en) | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs |
US4087547A (en) | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma |
US4054582A (en) | 1976-07-06 | 1977-10-18 | Eli Lilly And Company | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones |
US4208351A (en) * | 1976-11-10 | 1980-06-17 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4102902A (en) | 1976-11-10 | 1978-07-25 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4176233A (en) | 1976-11-10 | 1979-11-27 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4188495A (en) | 1977-11-14 | 1980-02-12 | Pfizer Inc. | 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor |
US4152450A (en) | 1978-02-17 | 1979-05-01 | Eli Lilly And Company | 9-Amino-dibenzopyrans |
US4171315A (en) | 1978-03-31 | 1979-10-16 | Eli Lilly And Company | Preparation of cis-hexahydrodibenzopyranones |
IL55274A (en) | 1978-08-02 | 1982-08-31 | Yissum Res Dev Co | 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them |
DE3025385A1 (de) | 1980-07-04 | 1982-01-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue tricyclische arylether, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
JPS5798228A (en) | 1980-12-10 | 1982-06-18 | Hisamitsu Pharmaceut Co Inc | Biphenyl derivative |
US4550214A (en) | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
US4395560A (en) | 1982-05-24 | 1983-07-26 | Eli Lilly And Company | Preparation of 6a,10a-trans-hexahydrodibenzopyranones |
US4497827A (en) | 1982-08-30 | 1985-02-05 | Syntex (U.S.A.) Inc. | Arachidonic acid analogues as anti-inflammatory and anti-allergic agents |
US4885295A (en) | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
JPS61126069A (ja) | 1984-11-21 | 1986-06-13 | Res Dev Corp Of Japan | プロスタグランジン誘導体 |
IL80411A (en) | 1986-10-24 | 1991-08-16 | Raphael Mechoulam | Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them |
US4833073A (en) | 1987-01-27 | 1989-05-23 | Hoffmann-La Roche Inc. | Immunoassay for tetrahydrocannabinol metabolites |
US4758597A (en) | 1987-05-15 | 1988-07-19 | University Patents, Inc. | Carenadiol and derivatives |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
KR900012875A (ko) | 1989-02-08 | 1990-09-03 | 오스카 아끼히꼬 | 비페닐 유도체, 신경세포 변성수복 또는 보호제 및 여기에 사용되는 폐닐유도체의 제조방법 |
JPH02304080A (ja) | 1989-05-17 | 1990-12-17 | Toyo Pharma- Kk | 6H―ジベンゾ[b,d]ピラン―6―オン誘導体,その製法及び用途 |
US5521215A (en) | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5284867A (en) | 1989-11-07 | 1994-02-08 | Yissum Research Development Company Of The Hebrew University In Jerusalem | NMDA-blocking pharmaceutical compositions |
US5068234A (en) | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
US6096740A (en) | 1990-11-06 | 2000-08-01 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions |
US5576436A (en) | 1991-08-01 | 1996-11-19 | Pharmaceutical Discovery Corporation | Fluorescent ligands |
US5538993A (en) | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5635530A (en) | 1991-09-12 | 1997-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5489580A (en) | 1992-11-05 | 1996-02-06 | University Of Connecticut | Phospholipid compounds and use therefor |
US5618955A (en) | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
US5440052A (en) | 1993-08-06 | 1995-08-08 | University Of Connecticut | Compositions useful as a cannabinoid receptor probe |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5434295A (en) | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
US5631297A (en) | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5605906A (en) | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
US5688825A (en) | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
US5760225A (en) | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5939429A (en) | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
ATE277921T1 (de) * | 1998-05-04 | 2004-10-15 | Univ Connecticut | Selektiv auf den cb2-rezeptor wirkende cannabinoide |
ATE247097T1 (de) | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
CA2337822A1 (en) | 1998-06-09 | 1999-12-16 | The University Of Connecticut | Inhibitors of the anandamide transporter as analgesic agents |
US7589220B2 (en) | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
AU1833600A (en) | 1998-11-24 | 2000-06-19 | Andreas Goutopoulos | Cannabimimetic lipid amides as useful medications |
US8084467B2 (en) | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
AU785033B2 (en) * | 1999-10-18 | 2006-08-31 | University Of Connecticut, The | Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
AU1969201A (en) | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US6943266B1 (en) | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
AU778159B2 (en) | 1999-10-18 | 2004-11-18 | University Of Connecticut, The | Peripheral cannabinoid receptor (CB2) selective ligands |
US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
KR20030008153A (ko) | 2000-06-22 | 2003-01-24 | 파모스 코포레이션 | 신규 비-향정신성 카나비노이드 |
US7329651B2 (en) | 2001-01-26 | 2008-02-12 | University Of Connecticut | Cannabimimetic ligands |
JP2005503998A (ja) | 2001-01-29 | 2005-02-10 | ユニバーシティ オブ コネチカット | 受容体選択性のカンナビミメティックアミノアルキルインドール |
WO2002088056A1 (en) * | 2001-05-02 | 2002-11-07 | Exxonmobil Chemical Patents Inc. | Xylene isomerization |
JP4312594B2 (ja) | 2001-07-13 | 2009-08-12 | ユニバーシティ オブ コネチカット | 新規な二環式及び三環式カンナビノイド |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
IL147941A0 (en) * | 2002-01-31 | 2002-08-14 | Pharmos Corp | Bicyclic cb2 cannabinoid receptor ligands |
EP1469842A4 (en) * | 2002-01-31 | 2006-04-26 | Pharmos Corp | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS |
CN1678303A (zh) | 2002-08-23 | 2005-10-05 | 康涅狄格大学 | 具有治疗作用的酮类大麻类 |
JP2005536554A (ja) | 2002-08-23 | 2005-12-02 | ユニバーシティ オブ コネチカット | 新規なビフェニル及びビフェニル様カンナビノイド |
-
2002
- 2002-07-11 JP JP2003511769A patent/JP4312594B2/ja not_active Expired - Fee Related
- 2002-07-11 US US10/483,482 patent/US7057076B2/en not_active Expired - Lifetime
- 2002-07-11 EP EP02749947A patent/EP1414775B1/en not_active Expired - Lifetime
- 2002-07-11 AU AU2002320430A patent/AU2002320430A1/en not_active Abandoned
- 2002-07-11 WO PCT/US2002/021961 patent/WO2003005960A2/en active Application Filing
- 2002-07-11 CA CA2452881A patent/CA2452881C/en not_active Expired - Lifetime
-
2006
- 2006-01-31 US US11/344,762 patent/US7285683B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2452881C (en) | 2012-03-06 |
EP1414775B1 (en) | 2012-12-19 |
CA2452881A1 (en) | 2003-01-23 |
AU2002320430A1 (en) | 2003-01-29 |
EP1414775A4 (en) | 2005-06-29 |
US7057076B2 (en) | 2006-06-06 |
US20040236116A1 (en) | 2004-11-25 |
EP1414775A2 (en) | 2004-05-06 |
JP2005504736A (ja) | 2005-02-17 |
US20060199957A1 (en) | 2006-09-07 |
WO2003005960A3 (en) | 2003-06-19 |
WO2003005960A2 (en) | 2003-01-23 |
US7285683B2 (en) | 2007-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4312594B2 (ja) | 新規な二環式及び三環式カンナビノイド | |
RU2232154C2 (ru) | Замещенные производные имидазола, способ введения фармацевтической композиции и способ лечения на основе этих соединений | |
US20040087590A1 (en) | Novel biphenyl and biphenyl-like cannabinoids | |
EP0181793B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
JP2005507875A (ja) | カンナビノイド受容体に作用する新規なピラゾール類似体 | |
WO1999057107A2 (en) | Cannabinoids selective for the cb2 receptor | |
US7446229B2 (en) | Bicyclic cannabinoids | |
JPH0578368A (ja) | 血栓症および血管痙攣疾患の治療に有用な7−オキサビシクロヘプタンイミダゾールプロスタグランジン類縁体 | |
CA2300204C (en) | Process to produce 4-hydroxy-2-oxo-pyrane derivates useful as protease inhibitors | |
WO2007144487A2 (fr) | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques | |
JP2009520710A (ja) | オキサフェナントレン誘導体 | |
FI78289C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara bicyklo/3.2.0/heptan-6-onoximeterderivat. | |
AU2004200538B2 (en) | Novel bicyclic and tricyclic cannabinoids | |
US4377704A (en) | Hetero-prostaglandin derivatives and processes for preparing them | |
EP0266246A1 (fr) | Dérivés d'imidazo[4,5-b]pyridinone-2, leur préparation et leur application en thérapeutique | |
JPH0730053B2 (ja) | 抗炎症性ベンゾオキサゾロン誘導体 | |
JP3857428B2 (ja) | 抗真菌剤 | |
EP0619821A1 (en) | HEXAHYDROFURO(2,3-b)FURANS AS PAF ANTAGONISTS | |
AU634286B2 (en) | Additional further novel alkanophenones | |
US5177207A (en) | 7-aryl and heteroaryl ethers of desacetylforskolin | |
US5132463A (en) | 1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists | |
KR20020058036A (ko) | 2-아릴퀴놀린 유도체, 그의 제조 방법 및 치료제로서의 용도 | |
GB2082176A (en) | Heteroprostaglandin derivatives and processes for preparing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090116 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090414 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090513 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120522 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130522 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |